Peptide Mapping of Monoclonal Antibody (mAb) Using Nexera Bio with Q-TOF Mass Spectrometer for Full Sequence Confirmation

Importance of the Topic

Monoclonal antibodies have emerged as a cornerstone in modern therapeutics thanks to their high specificity and clinical efficacy. Ensuring the structural integrity and sequence fidelity of both innovator biologics and biosimilars is essential for safety, regulatory compliance and batch-to-batch consistency. Peptide mapping by liquid chromatography coupled with mass spectrometry is a gold-standard method for confirming primary sequences and detecting modifications in antibody drugs.

Objectives and Study Overview

This application note evaluates the performance of a biocompatible Nexera Bio UHPLC system for reproducible profiling of tryptic digests of human IgG and a bevacizumab biosimilar. The study then employs a Q-TOF mass spectrometer (LCMS-9030) to confirm peptide identities through accurate mass matching. Key goals include assessing retention-time repeatability and achieving comprehensive sequence coverage for the biosimilar.

Methodology and Instrumentation

Sample Preparation:

• Human IgG and bevacizumab biosimilar (10 mg/mL) were reduced with dithiothreitol, alkylated with iodoacetamide, then digested with trypsin at 37 °C for 4 hours.
• Digests were acidified with trifluoroacetic acid, centrifuged, and the supernatant injected.

Chromatographic Conditions (Nexera Bio UHPLC):

• Column: Shim-pack GISS C18, 5 μm, 250 × 4.6 mm
• Mobile phases: 0.1% TFA in water (A), 0.1% TFA in acetonitrile (B)
• Gradient: 0–5% B at 0 min, to 50% at 85 min, 75% at 95–100 min, return to 0% at 103–115 min
• Flow rate: 1.0 mL/min, column temperature: 40 °C, injection volume: 50 µL, PDA detection at 210 nm

Mass Spectrometry Conditions (LCMS-9030 Q-TOF):

• Heated ESI in positive mode, TOF mass range 250–2500 m/z
• Interface temperatures: heat block 400 °C, DL 250 °C, interface 300 °C
• Nebulizing gas N₂ (3 L/min), drying gas N₂ (10 L/min), heating gas zero air (10 L/min)

Main Results and Discussion

Retention-time repeatability for six representative peaks in the IgG digest showed intra-day RSDs below 0.3% and inter-day RSDs below 0.5%, demonstrating robust UHPLC performance. UV chromatograms of the bevacizumab digest were virtually identical across injections.

Accurate mass analysis on the Q-TOF instrument detected all in silico tryptic peptides of bevacizumab, including large fragments (>6000 Da). Mass errors were maintained within ±2 ppm, enabling 100% sequence coverage (excluding known C-terminal lysine truncation). Extracted ion chromatograms confirmed consistent peptide profiles with retention-time RSDs around 0.1%.

Benefits and Practical Applications

• High retention-time precision supports reliable profiling in quality-assurance workflows.
• Accurate mass confirmation of peptides delivers unambiguous sequence validation.
• Full sequence coverage of mAb digests bolsters confidence in biosimilar characterization.
• Biocompatible UHPLC components resist acidic mobile phases, enhancing system durability.

Future Trends and Potential Applications

Integration of ion-mobility separation and higher-resolution mass analyzers will further enhance peak capacity and detailed structural elucidation. Automated sample preparation and data-analysis pipelines, powered by machine learning, promise faster throughput and deeper insights into post-translational modifications. Extending this workflow to next-generation biologics—such as bispecific antibodies and antibody-drug conjugates—will serve evolving biopharmaceutical R&D and manufacturing needs.

Conclusion

The combination of Nexera Bio UHPLC and LCMS-9030 Q-TOF mass spectrometry provides a robust, high-resolution platform for peptide mapping and sequence confirmation of monoclonal antibodies. Excellent retention-time precision, comprehensive sequence coverage and high mass accuracy make this approach ideally suited for structural characterization of both innovator biologics and biosimilars in research and quality-control settings.

References

1. Shimadzu Corporation. Peptide Mapping of Antibody Drugs by Nexera-i. Application News No. L488, 2015.
2. US FDA. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to Reference Product. Guidance for Industry, 2015.
3. MacLean B. et al. Skyline: An Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments. Bioinformatics, 2010.